| BRAF G469A + PI3KCA E545K |
Resistant to anti-EGFR therapy: 33/57 (57.9%) |
| BRAF V600E |
| KRAS G12A + PI3KCA E542K; KRAS G12C + PI3KCA E542K; KRAS G12V + PI3KCA E546K |
| KRAS G12D + FBXW7 W237*
|
| KRAS G12V + mTOR S2215Y |
| KRAS Q61R + PTEN loss+ HER2 T862A |
| KRAS G12C/G12D/G12S/G12V/G13D/G13R |
| NRAS G12D + NF1 F843Sfs*35 + ATM c.[3577-1G>T] |
| NRAS Q61R |
| PIK3CA H1047R |
Associated with low-response to Anti-EGFR therapy: 10/57 (17.5%) |
| PTEN L100Tfs*
|
| PTEN loss + NF1 S1864Rfs*3 + NF1 D1866Rfs*17 |
| HER2 G776V + FBXW7 R658*
|
| HER2 V842I + PIK3CA E545K |
| HER2 amplification |
| HER2 amplification + ERG-TMPRSS2 fusion |
| BRCA1 Q148*
|
Approved anti-EGFR therapy: 14/57 (24.6%) |
| CCND2 amplification |
| NF1 R1306* + EGFR amplification |
| None actionable alterations detected |
